This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vidofludimus

4SC AG

Drug Names(s): SC12267, 4SC-101

Description: SC12267, a small molecular active agent, is a dihydroorotate dehydrogenase (DHODH) inhibitor. DHODH is involved in the biosynthesis of pyrimidine, and its inhibition may slow proliferation of fast proliferating cells, in particular lymphocytes used for immune response.

Deal Structure: In May 2004, 4SC and Serono signed an agreement under which 4SC granted Serono exclusive worldwide rights to develop and commercialize 4SC's program of dihydroorotate dehydrogenase (DHODH) inhibitors. The agreement covered lead compound SC12267 as well as further back-up compounds and related intellectual property. Under the terms of the agreement, 4SC received an upfront payment, research funding and potential milestone payments related to development progress, regulatory submissions, marketing authorizations and commercial sales achievements. If products are successfully developed, registered and commercialized, 4SC could receive up to USD67 million from Serono. 4SC will alsoreceive undisclosed royalties on product sales. 4SC will be responsible for completion of the multiple dose Phase I study on SC12267, while Serono will be solely responsible for further development, regulatory approvals and commercialization, both of SC12267 and of any other products deriving from...See full deal structure in Biomedtracker


Vidofludimus News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug